Physicians > Dr. Cosgriff,
M.D.
THOMAS M.
COSGRIFF, M.D.
CURRICULUM VITAE
Crescent City Research Consortium, LLC
1111
Medical Center Blvd.. Ste. N701
Marrero, LA 70072
Date
of Birth: June 5, 1945; Minneapolis
Education:
BA, cum laude, University of Minnesota,
Minnesota 1967
BS, University of Minnesota, Minnesota
1970
MD, University of Minnesota, Minnesota
1970
Internship (Internal Medicine), SUNY at
Buffalo, New York 1970-71
Residency (Internal Medicine), Brooke
Army Medical Center, Houston, Texas 1973-75
Fellowship (Hematology-Oncology),
University of Utah, Salt Lake City, Utah 1976-78
Medical Statistics, National Institutes
of Health, 1979, 1980
Immunohematology and Blood Transfusion,
National Institutes of Health, 1981
Mechanics of IND’s and NDA’s, Center for
Professional Advancement, 1982
Good Laboratory Practice, Center for
Professional Advancement, 1985
Hematopathology Annual Course, Armed
Forces Institute of Pathology, 1985
Education in Palliative and End-of-life
Care, 2004
Good Clinical Practice, Aureus Research
Consultants, 2005
Advanced Cardiac Life Support, 1980-2004
Advanced Trauma Life Support, 1992
Professional Appointments:
Ward
Officer and Chief of Professional Services, US Army Drug
Treatment Center, Long Binh, Vietnam, 1971-72
Chief, Outpatient Clinic, McDonald Army Hospital, For
Eustis, VA, 1972-73
Chief, Department of Medicine, For Monmouth, NJ, 1975-76
Investigator, Division of Experimental Therapeutics,
Walter Reed Army Institute of Research (WRAIR), 1978-85
Director, Coagulation Laboratory, United States Army
Medical Research Institute of Infectious Diseases
Chief, Department of Clinical Investigation, USAMRIID,
1981-85
Chief, Medical Division, USAMRIID, 1985-89
Attending Physician, Department of Medicine Walter Reed
Army Medical Center, 1978-79
Clinical Assistant Professor of Medicine, Uniformed
Services University of Health Sciences, 1980-87
Clinical Associate Professor of Medicine, Uniformed
Services University of Health Sciences, 1988-89
Chief, Hematology-Oncology Service, Fitzsimons Army
Medical Center (FAMC), 1989-1993
Associate Clinical Professor of Medicine, University of
Colorado Health Sciences Center, 1990-1993
Staff
Physician, Department of Medicine, East Jefferson
Hematology Oncology, Metairie, LA 1994 –Present
Chairman, Division of Palliative Medicine, East
Jefferson General Hospital, Metairie, LA 2005-Present
Staff
Physician, Jefferson Oncology Clinic, Metairie, LA,
1994-1996
Staff
Physician, Hematology and Oncology Specialists, LLC, New
Orleans, LA 1997 –2012
Chairman, Medical Committee & Research Committee,
Hematology and Oncology Specialists, New Orleans, LA,
1997 –2005 (remain a member
Member, Executive Committee, Hematology & Oncology
Specialists, LLC, New Orleans, LA 2005-
Professional Certification:
Internal Medicine (1975)
Recertification (1987, 1997)
Medical Oncology (1997) Recertification
(1997, 2006)
Hospice and Palliative Medicine (2005)
Research Experience:
Laboratory and Clinical Investigation of
Coagulation Abnormalities, University of Utah, 1976-78
Laboratory and Clinical Investigation of Hemostatic
Derangement Produces by Infectious and Toxic Agents,
USAMRIID, 1978-89
Investigator, Clinical Drug Studies, WRAIR and USAMRIID,
1978-89
Investigator, Clinical Studies, USAMRIID, 1985-89
Research Adviser, National Research Council
Associateship Program, 1985-89
Principal Investigator, FAMC, Southwest Oncology Group
Clinical Trials, 1990-1993
Principal Investigator, Clinical Trials, Hematology and
Oncology Specialists, New Orleans, LA 1997 -
Military Service
United States Army Medical Corps
1971-1976, 1978-1993
Retired with rank of Colonel 1993
Awards and Honors:
Civilian
Phi Beta Kappa, 1967
Karl Wilheml Stenstrom Student Award for
Research in Radiation
Biology, University of Minnesota
Medical School, 1970
Fellow, American College of Physicians,
1984
American Cancer Society Spirit Award,
2005
Military
Vietnam Service Medal
Republic of Vietnam Campaign Medial
Bronze Star for Meritorious Service
Army Commendation Medal
Meritorious Service Medal
Legion of Merit
Award of the Professional “A” designator
by the Surgeon General of the Army, 1988
Commander’s Award, USAMRIID
Memberships:
American Academy of Hospice and
Palliative Medicine
American Association for the Advancement
of Science
American College of Physicians
American Society of Clinical Oncology
American Society of Hematology
International Society on Thrombosis and Haemostatsis
PUBLICATIONS
1.
Cosgriff TM.
The metobolic effects of the periwinkle alkaloid
vinblastine. Minn Med 1986; 51:977-982
2.
Cosgriff TM.
Causation as it relates to cancer theory. Minn Med
1968; 51:983-988
3.
Cosgrff TM.
The effect of vinblastine on compensatory renal growth.
Growth 1970: 34:187-196
4.
Cosgriff TM.
Internal and external elements in a community health
curriculum. The New Physician 1970: 19:46-47
5.
Cosgriff TM.
Anisocoria in heoin withdrawal. Arch Neurol
1973;29:200-201
6.
Cosgriff TM,
and Arnold WJ. Digital vasospasm and infarction
associated with hepatitis B antigenemia. JAMA 1976;
245:1362-1363
7.
Cosgriff TM,
Olin DB, and Nash DA, Jr.; Hyporeninemic
hypoaldosteronism—case report and observation of
dissociated renin and erythropoietin activity. J Chron
Dis 1978; 31:195-200
8.
Ririe DG, Cosgriff TM, and
Martin B. Central retinal vein occlusion in a patient
with familial antithrombin III deficiency: case report.
Ann Ophthalmol 1979; 11:1844-1845
9.
Kitahara M, Cosgriff TM, and
Eyre HJ. Sideroblastic anemia as a preleukemic event in
patients treated for Hodgkin’s Disease. Ann Intern Med
1979; 92:625-627
10.
Cosgriff TM.
Doxorubicin and ventricular arrhythmia. Ann Intern Med
1980; 92:434-435 (letter)
11.
Cosgriff TM,
and Martin B. Low functional and high antigenic
antithrombin III level in a patient with the lupus
anticoagulant and recurrent thrombosis. Arth Rheum
1981; 24:94-96
12.
Cosgriff TM
and McCloskey DW. Hodgkin disease as the terminal
malignancy in Richter syndrome. Med Ped Oncol 1981;
9:265-272
13.
Chen DS, Cosgriff TM, and
Kitahara M. Long-term survival in Wiskott-Aldrich
syndrome: case report and literature review. Am J Med
Sci 1981; 282:85-90
14.
Cosgriff TM,
Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RA,
and Canfield CJ. Evaluation of the antimalarial
activity of the phenanthrenemethanol halofantrine (WR
171, 669). Am J Trop Med Hyg 1982; 21:1075-1079
15.
Cosgriff TM,
Hodgson LA, and West JV. The antithrombin III content
of blood collected with and without heparin. Vox Sang
1983: 44:98-101
16.
Cosgriff TM,
Bishop DT, Hershgold EJ, Skolnick MH, Martin BA, Baty
BJ, and Carlson KS. Familial antithrombin III
deficiency: its natural history, genetics, diagnosis
and treatment. Medicine 1983; 62:209-220
17.
Cosgriff TM,
Hershgold EJ, Martin BA, and Carlson KS. False
assignment of familial antithrombin III deficiency with
the von Kaulla assay. Am J Clin Pathol 1983; 80:697-699
18.
Cosgriff TM.
Blood screening for hepatitis in induced malaria. Am J
Trop Med Hyg 1983; 32:908-909 (letter)
19.
Canonico PG, Kastello MD, Cosgriff
TM, Donovan JC, Ross PE, Spears CT, and Stephen EL.
Hematological and bone marrow effects of ribavirin in
rhesus monkeys. Toxical Appl Pharmacol 1984; 74:163-172
20.
Cosgriff TM,
Boudreau EF, Pamplin CL, Berman JD, Shmuklarsky MJ, and
Canfield CJ. Evaluation of the 4-pyridinemethanol WR
180, 409 in the treatment of induced Plasmodium
falciparum infections in healthy non-immune subjects.
Am J Trop Med Hyg 1984; 33:767-771
21.
Cosgriff TM,
Hodgson LA, Canonico PG, White JD, Kastello MD, Donovan
JC, and Ross PE. Morphological alterations in blood and
bone marrow of ribavirin-treated monkeys. Acta Haematol
1984; 72-195-200
22.
Cosgriff TM,
Bunner DP, Wannemacher RW Jr, Hodgson LA, and Dinterman
RE. The hemostatic derangement produced by T-2 toxin in
guinea pigs. Toxical Appl Pharmacol 1984; 76:454-463
23.
Cosgriff TM,
Pamplin CL, Canfield CJ. Mefloquine failure in a case
of falciparum malaria induced with a
multi-drug-resistant isolate in a non immune subject.
Am J Trop Med Hyg 1985; 34:692-693
24.
Brunner, DL, Wanner RW Jr, Neufeld
HA, Hassler CR, Parker GW, Cosgriff TM, and
Dinterman RE. Pathophysiology of acute T-2 intoxication
in the cynomolgus monkey and rat models. In: Lacey J,
ed. Trichothecene and Other Mycotoxins. New York: John
Wiley and Sons; 1985:411-421
25.
Chulay JD, Schneider I, Cosgriff
TM, Hoffman SL, Ballou WR, Quakyi IA, Trosper JH,
and Hockmeyer WT. Malaria transmitted to man by
mosquitos infected from cultured Plasmodium falciparum.
Am J Trop Med Hyg 1986; 35:66-68
26.
Cosgriff TM,
Bunner DL, Wannemacher RW Jr, Hodgson LA, and Dinterman
RE. The hemostatic derangement produced by T-2 toxin in
cynomolgus monkeys. Toxical Appl Pharmacol 1986;
82:532-539
27.
Bunner DL, Wannemacher RW, Parker GW,
Neufeld HA, Pace JG, Thompson W, Cosgriff TM, and
Hassler CR. Acute trichothecene intoxication in
animals. Proceedings of the VI International Conference
on the Mycoses. PAHO Scientific Publication No. 478;
1986:47-56
28.
Cosgriff TM,
Jahrling PB, Chen JP, Hodgson LA, Lewis RM, Green DE,
and Smith JI. Studies of the coagulation system in
arenaviral hemarrhagic fever: experimental infection of
strain 13 guinea pigs with Pichinde virus. Am J Trop
Med Hyg 1987; 36:424-431
29.
Lewis RM, Cosgriff TM, Peters
CJ, and Morrill JC. Differentiation of a human moncyte
cell line associated with increased production of Rift
Valley fever virus by infected cells. J Med Virol 1987;
23:207-215
30.
Yuan GH, Guang MY, Wu ZO, Zhou WH,
Zhang TM, Liu XM, Huggins JW, Cosgriff TM, and
Smith JI. Observations on dynamic change of creatinine
clearance rate (ccr) in different types of epidemic
hemorrhagic fever with renal syndrome (EHRS). Chinese
journal Internal Medicine 1987; 26:458-460
31.
Zhang TM, Huggins JW, Zheng ZM,
Cosgriff TM, Yang, ZQ, Smith JI, Jiang WL, Hsiang
CM, Hang CZ, Wu ZO, Guang MY, Yuan GH, Hu JJ, Zhou WH,
Niu CS, and Zhang TH. Clinical observations on
ribavirin therapy in early phase patients with epidemic
hemarrhagic fever. Chinese pharmaceutical bulletin
1987: 22:246-248
32.
Wu ZO, Guang MY, Yuan GH, Hang CZ,
Huang QT, Wang JZ, Pang LK, Hu JJ, Zhou WH, Niu CS,
Zhang TH, Zhang TM, Huggins JW, Cosgriff TM, and
Smith JI. Ribavirin in the treatment of early stage
epidemic hemarrhagic fever. Acta Acadamiae Medicinae
Hubei 1987; 8:140-144
33.
Xiao SY, Zhu BL, Zhang TM, Zheng ZM,
Hsiang CM, Meegan JM, LeDuc JW, Huggins JW, Cosgriff
TM, and Smith JI. Effect of ribavirin on specific
humoral immune responses in patients with hemorrhagic
fever with renal syndrome (HFRS). Chinese Journal
Virology 1987; 3:243-247
34.
Xiao SY, Zhu BL, Zhang TM, Zheng ZM,
Hsiang CM, Meegan JM, LeDuc JW, Huggins JW, Cosgriff
TM, and Smith JI. Effect of ribavirin on serum IgG
and IgM response in patients with hemorrhagic fever with
renal syndrome (HFRS). Chinese Journal of Virology
1987; 3:243-247
35.
Xiang CM, Guang MY, Wang JN, Zheng
ZM, Wu ZO, Ge ZQ, Zhang TM, Yuan GH, Gui XE, Huggins JW,
Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM.
Study of antiviral-specific therapy of epidemic
hemorrhagic fever with ribavirin. Chinese Journal
Experimental Clinical Virology 1988; 2:47-52
36.
Lewis RM, Cosgriff TM, Griffin
BY, Rhoderick J, and Jahrling PB. Immune serum
increases arenavirus replication in monocytes. J Gen
Virol 1988; 69:1735-1739
37.
Zhang TM, Xiang JM, Niu CS, Zhou WH,
Zhang TH, Huggins JW, Cosgriff TM, Smith JI.
Effects of ribavirin on white blood cells and platelets
in patients with epidemic hemorrhagic fever. Chinese
Journal Immunology 1988; 4:287-289
38.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Zhang MY, Smith JI, Zheng ZM, LeDuc JW,
Hsiang CM, and Meegan JM. Analysis of antigenic
differences among 40 hemorrhagic fever with renal
syndrome (HFRS) virus strains isolated from Hubei by
monoclonal antibody. Acta Acadamiae Hubei 1988;
9:307-308
39.
Cosgriff TM
and Lewis RM. Introduction and summary: International
Symposium on Hemostatic Impairment Associated with
Hemorrhagic Fever Viruses. Rev Infect Dis 1989; 11
(Suppl 4): S669-S671
40.
Cosgriff TM.
Viruses and hemostasis. Rev Infect Dis 1989; 11 (Suppl
4):S672-S688
41.
Lewis RM, Morrill JC, Jahrling PB,
and Cosgriff TM. Replication of viral
hemorrhagic fever viruses in monocytic cells. Rev Infect
Dis 1989; 11 (Suppl 4): S736-S742
42.
Cosgriff TM,
Morrill JC, Jennings GB, Hodgson LA, Slayter MV, Gibbs
PH, and Peters CJ. Hemostatic derangement produced by
Rift Valley fever virus in rhesus monkeys. Rev Infect
Dis 1989; 11(Suppl 4): S807-S814
43.
Morrill J, Jennings G, Cosgriff TM,
Gibbs P, and Peters CJ. Prevention of Rift Valley Fever
in rhesus monkeys with interferon-x. Rev Infect Dis
1989; 11 (Suppl 4) : S815-S825
44.
Fan WF, Yu S, and Cosgriff TM.
The reemergence of dengue in China. Rev Infect Dis
1989; 11 (Suppl 4): S847-S853
45.
Guang MY, Liu GZ, and Cosgriff TM.
Hemorrage in hemorrhagic fever renal syndrome in China.
Rev Infect Dis 1989; 11 (Suppl 4): S884-S890
46.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Smith JI, Niu CS, Zhou WH, and Zhang
TH. Observations on hematological changes in epidemic
hemorrhagic fever. Acta Acadamiae Medicinae Hubei 1989;
10:197-200
47.
Cosgriff TM.
Hemorrhagic fever with renal syndrome: Four decades of
research. Ann Intern Med 1989; 110:313-316
48.
Yang ZQ, Zhang TM, Zhang MY, Hu ZJ,
Zheng ZM, Qu CF, Chu BL, Hsiang CM, Huggins JW,
Cosgriff TM, and Smith JI. Study of viremia during
the febrile phase in patients with epidemic hemorrhagic
fever and its relation to disease manifestations.
National Medical Journal of China 1990; 70:15-18
49.
Yuan GH, Huggins JW, Zhang JR,
Cosgriff TM, Guang MY, Smith JI, Wang SJ, and Wu
ZO: Calculation of normal values for creatinine
clearance from study of 251 healthy persons. Chinese
Journal Internal Medicine 1990; 29:227-228
50.
Morrill JC, Jennings GB, Johnson AJ,
Cosgriff TM, Gibbs PH, and Peters CJ.
Pathogenesis of Rift Valley fever in rhesus monkeys:
role of interferon response. Arch Virol 1990;
110:195-212
51.
Xiang LB, Zhang ZY, Chen JM, Xiang
JM, Cosgriff TM. Epidemic hemorrhagic fever: the
mechanism of coagulation and fibrinolysis derangment.
Chin Med J 1990; 103:391-395
52.
Gordon DM, Cosgriff TM,
Schneider I, Wasserman GF, Majarin WR, Hollingdale MR,
and Chulay JD. Safety and immunogenicity of a
Plasmodium vivax sporozoite vaccine. Am J Trop Med Hyg
1990; 42:527-531
53.
Cosgriff TM.
Pulmonary edema in falciparum malaria: slaying the
dragon of volume overload. Chest 1990; 98:10-12
(editorial)
54.
Yang ZQ, Zhang TM, Zhang MV, Zheng
ZM, Hu ZJ, Qu CF, Xiang JM, Huggins JW, Cosgriff TM,
and Smith JI. Interruption study of viremia in patients
with hemarrhagic fever with renal syndrome in the
febrile phase. Chinese Medical Journal 1991; 104:
149-153
55.
Cosgriff TM.
Mechanisms of disease in hantavirus infection: the
pathophysiology of hemorrhagic fever with renal
syndrome. Rev Infect Dis 1991; 13: 97-107
56.
Lewis RM, Lee HW, See AF, Parrish DB,
Moon JS, Kim DJ, and Cosgriff TM. Changes in
populations of immune effector cells during the course
of haemorrhaic fever with renal syndrome. Trans Roy Soc
Trop Med Hyg 1991; 85:282-286
57.
Cosgriff TM,
Lee HW, See AF, Parrish DB, Moon JS, Kim DJ, and Lewis
RM. Platelet dysfunction contributes to the haemostatic
defect in haemorrhagic fever with renal syndrome. Trans
Roy Soc Trop Med Hyg 1991; 85:660-663
58.
Cosgriff TM,
and Lewis RM. Mechanisms of disease in hemorrhagic
fever with renal syndrome. Kidney Int 1991: 40(Suppl
35): S72-S79
59.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, WuZO, LeDuc JW, Zheng ZM, Meegan JM,
Wang QN, Oland DD, Gui XE, Yuan GH, and Zhang TM.
Prospective, double-blind, concurrent,
placebo-controlled clinical trial of intravenous
ribavirin therapy of hemorrhagic fever with renal
syndrome. J Infect Dis 1991; 164:1119-1127
60.
Veloso D, Smith JI, Denny S., and
Cosgriff TM. Structure, kinetics, and function of
human and rhesus plasma prekallikreins are similar.
Thromb Haemostas 1992; 68:526-533
61.
Yuan J, Huggins JW, Guang MY,
Cosgriff TM, and Smith JI. Rapid calculation of
creatinine clearance rate in normal subjects and in
patients with epidemic hemorrhagic fever. Chines
Journal Internal Medicine 1992; 31:701-704
62.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Zhang MY, Smith JI, Hu ZJ, and Hsiang
CM. Analysis of viremia and clinical findings in
patients with epidemic hemorrhagic fever. Chinese
Medical Journal ( in press)
63.
Zhang TM, Yang ZQ, Zhang MY, Hu ZJ,
Xiang JM, Huggins JW, Cosgriff TM, and Smith JI.
Early analysis of viremia and clinical tests in patients
with epidemic hemorrhagic fever. Chinese Medical
Journal 1993; 106:608-610
64.
Lum GH, Cosgriff TM, Byrne R,
and Reddy V. Primary T-cell lymphoma of muscle in a
patient infected with human immunodeficiency virus.
Amer J Med 1993; 95:545-546
65.
Veloso D,
Denny S, Cosgriff TM, and Hochstein HD.
Differential
suspectibility of rhesus monkeys to high doses of
endotoxin. J Endotox Res 1995; 2:411-420
66.
Cosgriff TM,
Black ML, Stein W III. Successful treatment of
refractory idiopathic thrombocytopenic purpura with
liposomal doxorubicin. Amer J Hematol 1998; 57:85-86
67.
Veloso
D, Smith JI, and Cosgriff, TM. Rhesus
differential susceptibility to endotoxin is not
associated with activation of plasma prekllikrein.
Immunopharmacol 1999; 43:265-271
68.
Chen JP and Cosgriff, TM.
Hemorrhagic fever virus-induced changes in hemostasis
and vascular biology. Blood Coagul Fibrinolysis 2000;
11:461-483
69.
Chong C. Bhatnagar A, Cunningham D,
Cosgriff, T, Harper P, Steward W, Birdgewater J,
Moore M, Casssidy J, Coleman R, Coxon F, Redfern C,
Jones J, Hawkins R, Northfelt A, Sreedharan S, Valone F,
and Carmichael J. Phase III trial of 5fu and leucovorin
plus either 3HI anito-idiotype monoclonal antibody (Cea
Vac) Or placebo in patient with advanced colorectal
cancer. Submitted for Publication.
ABSTRACTS
1.
Bishop DT, Martin B, Baty B,
Cosgriff TM, Hershgold E, and Skolnick M. Linkage of
antithrombin III deficiency to Duffy blood group. Am J
Human Genetics 1978; 30:48A
2.
Lui CT, Griffin MJ, Jahrling PB,
McNamee GA, Cosgriff TM, and Peters CJ.
Phyiological responses of strain 13 guinea pigs to
Pichinde virus infection. Fed Proc 1982; 41:1133A
3.
Kastello MD, Cosgriff TM,
Canonico PG, Wannarka GL, and Spears CT. Effect of
ribavirin on blood and bone marrow of monkeys.
Proceedings of the Annual Meeting of the American
Society of Toxicology, Boston, Massachusetts, March 1982
4.
Cosgriff TM,
Boudreau EF, Pamplin CL, and Canfield CJ. The
antimalarial activity of the pyridinemethanol WR 180,
409. Proceedings of the 2nd International
Conference on Malaria and Babesiosis, Annecy, France,
September 1983
5.
Johnson ED, Cosgriff TM, and
McKee KT, Jr. Experimental Ebola hemorrhagic fever
(EHF) in rhesus macaques. Proceedings of the Annual
Meeting of the American Society of Tropical Medicine and
Hygiene, San Antonio, Texas, December 1983
6.
Cosgriff TM.
Hemostatic derangement in T-2 toxicosis. Proceedings of
the FASEB Conference on Mycotoxins, Saxtons, River,
Vermont, June 1984
7.
Cosgriff TM.
New antimalarial drugs under development by the US Army.
Proceedings of the XIth International Conference of
Tropical Medicine and Malaria, Calgary, Alberta,
September 1984
8.
Cosgriff TM,
Hodgson LA, Lewis RM, and Driessen JL. Familial
thrombopathy with increased activity of factors V, VII,
and VIIIc. Blood 1984; 64(suppl 1):975A
9.
Lewis RM, Johnson ED, Jahrling PB,
Edgell C-J, Cosgriff TM, and Peters CJ. In vitro
infection of endothelial cells by Ebola, Lassa and
Marburg viruses. Proceedings of the Annual Meeting of
the American Society of Microbiology, Las Vegas, Nevada,
March 1985
10.
Johnson ED, McKee KT Jr, Jaax N,
Dixon J, Lewis RM, and Cosgriff TM. Experimental
Ebola hemorrhagic fever (EHF): a model for rational
therapy. Poceedings of the 4th International
Congress on the Impact of Viral Diseases on the
Development of the African and Middle East Countries,
Rabat, Morocco, April 1985
11.
Cosgriff T,
Hodgson L, Lewis R, Fair D, and Marlar R. Familial
protein S deficiency associated with increased activity
of factors V, VII, and VIIIc, and recurrent thrombosis.
Thromb Haemost 1985; 54:219A
12.
Cosgriff T,
Jahrling P, Green D, and Hodgson L. The coagulation
system in viral hemorrhagic fever: Pichinde virus
infection of strain 13 guinea pigs. Thromb Haemost
1985; 54:898A
13.
Cosgriff T,
Morrill J, Jennings G, Peters C, and Hodgson L. Rift
Valley Fever Virus in rhesus virus in rhesus monkeys
produces multiple hemostatic abnormalities which are
prevented by
a-interferon.
Throm Haemost 1985;54:907A
14.
Lewis RM, Hodgson LA, and Cosgriff
TM. T-2 effects on tissue factor production by human
monocytes and U937 cells. Thromb Haemost 1985; 54:1174A
15.
Johnson ED, McKee KT Jr, Jaax N,
Dixon S, Lewis R, and Cosgriff T. Filovirus
infections of rhesus macaques. Proceedings of the Annual
Meeting of the American Society of Tropical Medicine and
Hygiene, Miami, Florida, November 1985
16.
Milhous WK, Gerena L, and Cosgriff
TM. In vitro induction of resistance to WR 180, 409
(Enpiroline) in a cloned isolate of Plasmodium
falciparum. Proceedings of the Annual Meeting of the
American Society of Tropical Medicine and Hygiene,
Miami, Florida, November 1985
17.
Cosgriff TM.
In vivo and in vitro effects of T-2 toxin on platelets.
Proceedings of the FASEB Conference on Trichothecene
Mycotoxins, Copper Mountain, Colorado, July 1986
18.
Huggins JW, Hsiang CM, Cosgriff TM,
Wu ZO, Meegan JM, LeDuc JW, Zheng ZM, Smith JI, Ge XQ,
Guang MY, Wang QN, Zhang TM, Yuan GH, and Gui XE.
Double-blind, placebo-controlled clinical trial of
ribavirin therapeutic efficacy in the treatment of
epidemic hemorrhagic fever: open phase for dose
setting. Proceedings of the IXth International Congress
of Infectious and Parasitic Disease, Munich, Federal
Republic of Germany, July 1986
19.
Cosgriff, TM.
Viruses and hemostasis. Proceedings of the International
Symposium on Hemostatic Impairment Associated with
Hemorrhagic Fever Viruses, Leesburg, Virginia, May 1987
20.
Guang MY, Liu GZ, and Cosgriff TM.
Hemorrhage in hemorrhagic fever with renal syndrom in
China. Proceedings of the International Symposium on
Hemostatic Impairment Associated with Hemorrhagic Fever
Viruses, Leesburg, Virginia, May, 1987
21.
Cosgriff TM,
Morrill JC, Jennings GB, Hodgson LA, Slayter MV, Gibbs
PH, and Peters CJ. The hemostatic derangements produced
by Rift Valley fever virus in rhesus monkeys.
Proceedings of the International Symposium on Hemostatic
Impairment Associated with Hemorrhagic Fever Viruses,
Leesburg, Virginia, May 1987
22.
Lewis RM, Morrill JC, Jahrling PB,
and Cosgriff TM. U937 cells as an in vitro model
of hemorrhagic fever virus infection. Proceedings of
the International Symposium on Hemostatic Impairment
Associated with Hemorrhagic Fever Viruses, Leesburg,
Virginia, May 1987
23.
Jahrling PB, Liu CT, and Cosgriff
TM. The Pichinde model of arenavirus hemorrhagic
disease. Proceedings of the International Symposium on
Hemostatic Impairment Associated with Hemorrhagic Fever
Viruses, Leesburg, Virginia, May 1987
24.
Hsiang CM, Huggins JW, Guang MY,
Cosgriff TM, Zheng ZM, Smith JI, Wu WO, Wang QN,
LeDuc JW, Ge XQ, Meegan JM, Gui XE, and Zhang TM.
Effective therapy of epidemic hemorrhagic fever with
ribavirin in a double-blind, randomized, controlled
trial. II. Improvement in some clinical signs:
hematology, cardiology, nephrology, and immunology.
Proceedings of the 29th International
Colloquium on Hantaviruses, Antwerp, Belgium, July 1987
25.
Cosgriff TM,
Canonico PG, Hodgson L, Parrish D, Chapman T, Huggins
JW, Gong ZJ, Xiang LB, and Hsiang CH. Ribavirin:
studies on the effects of the antiviral drug on platelet
function. Thromb Haemost 1987; 58:1746A
26.
Lewis RM, Jahrling PB, Griffin BP,
and Cosgriff TM. The effect of hemorrhagic fever
virus infection of endothelial cells. Throm Haemost
1987; 58:553A
27.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH and Zhang TM. Clinical
therapeutic efficacy of high dose intravenous ribavirin
treatment of hemorrhagic fever with renal syndrome
(HFRS): randomized, double-blind, placebocontrolled
trial in the Peoples Republic of China. Proceedings of
the VIIth International Congress of Virology, Edmonton,
Alberta, August 1987
28.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH, and Zhang TM, and Lee HW.
Intravenous ribavirin therapy of hemorrhagic fever with
renal syndrom. Proceedings of the XVIth Pacific Science
Conference, Seoul, Korea, August 1987
29.
Cosgriff TM,
Parrish DB, Jahrling PB, Huggins JW, Lewis RM, and
Peters CJ. The original hemorrhagic fever revisited:
hemostatic derangement in rhesus monkeys infected with
yellow fever virus. Thromb Haemost 1987; 70:369A
30.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH, Zhang TM and Lee HW.
Intravenous ribavirin therapy of hemorrhagic fever with
renal syndrome (HFRS). Proceedings of the Annual Meeting
of the American Society of Tropical Medicine and
Hygiene, Los Angeles, California, November 1987
31.
Fajfar-Whetstone CJ, Kakoma I, Hansen
R, Buese M, Ristic M, and Cosgriff TM. Analysis
of Plasmodium falciparum-specific antibodies on
sequential serum samples from infected human volunteers,
using the immunoflourescent and antibody test, Western
immunoblotting and an in vitro neutralization assay.
Proceedings of the Annual Meeting of the American
Society of Tropical Medicine and Hygiene, Los Angeles,
California, November 1987
32.
Jahrling, PB, Peters CJ, Huggins JW,
Cosgriff TM, and Monath TP. Ribavirin therapy of
yellow fever. Proceedings of the Annual Meeting of the
American Society of Tropical Medicine and Hygiene, Los
Angeles, CA, November 1987
33.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Smith JI, Niu CS, Zhou WH, and Zhang
TH. Study of the effects of ribavirin on red blood cells
in patients with epidemic hemorrhagic fever.
Proceedings of the Second Chinese National Conference on
Nucleoside and Nucleotide Drugs, Beijing, Peoples’
Republic of China, December 1987
34.
Jahrling PB, Trotter RW, Barrer Oro
JG, Lupton HW, Cosgriff TM, Lewis RW, Parrish DB,
Smith SB, and Peters CJ. Cross-Protection against
Machupo with Candid #1 live, attenuated Junin virus
vaccine. III. Post challenge clinical findings.
Proceedings of the 2nd International
Conference on the Impact of Viral Diseases on the
Development of Latin American Countries and the
Caribbean region, Mar del Plata, Argentina, March 1988
35.
Hsiang CM, Guang MY, Wang QN, Zheng
ZM, Wu ZO, Ge XQ, Zhang TM, Gui XE, Huggins JW,
Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM.
Effective therapy of epidemic hemorrhagic fever patients
with ribavirin: decreased mortality and reversible
anemia. Proceedings of the Second International
Conference on Antiviral Research, Williamsburg,
Virginia, March 1988
36.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Smith JI, and Niu CS. A study of the
effects of ribavirin on white blood cells and platelets
in patients with epidemic hemorrhagic fever. Proceedings
of the 2nd International Conference on
Antiviral Research, Williamsburg, Virginia, March 1988
37.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and
Oland DD. Intravenous ribavirin therapy for hemorrhagic
fever with renal syndrome (HFRS). Proceedings for the 2nd
International Conference on Antiviral Research,
Williamsburg, Virginia, March 1988
38.
Hsiang CM, Guang MY, Wang QN, Zheng
ZM, Wu ZO, Ge XQ, Zhang TM, Gui XE, Huggins JW,
Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM.
Effective therapy of epidemic hemorrhagic fever patients
with ribavirin: decreased mortality and reversible
anemia. Antiviral Research 1988; 9:147A
39.
Cosgriff, TM.
The pathophysiology of hemorrhagic fever with renal
syndrome. Presented at the One Day Symposium on
Hemorrhagic Fever with Renal Syndrome, Frederick,
Maryland, March, 1988
40.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Smith JI, and Niu CS. A study of the
effects of ribavirin on white blood cells and platelets
in patients with epidemic hemorrhagic fever. Antiviral
Res 1988; 9:148A
41.
Huggins JW, Cosgriff TM, Smith
JI, LeDuc JW, Meegan JM, Hsiang CM, Guang MY, Wu ZO,
Zhang TM, and Lee HW. Intravenous ribavirin therapy for
Korean hemorrhagic fever (Korea) – epidemic hemorrhagic
fever (China). Proceedings of the Annual Meeting of the
Society of Armed Forces Medical Laboratory Scientists,
Reno, Nevada, April 1988
42.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Niu CS, Smith JI, Zhou WH, and Zhang
TH. A study of the effects of ribavirin on white blood
cells and platelets in patients with epidemic
hemorrhagic fever. Proceedings of the International
Symposium on Viral Diseases: Prevention, Strategy, and
Therapy, Shanghai, People’s Republic of China, May 1988
43.
Xiang LB, Cosgriff TM, and
Hsiang CM. Improvement of some hematological parameters
in ribavirin-treated epidemic hemorrhagic fever patients
in Hubei, China. Antiviral Res 1988; 9:148A
44.
Jahrling PB, Trotter RW, Barrera Oro
JG, Lupton HW, Cosgriff TM, and Peters CJ.
Cross-protection against Machupo with Candid #1 live,
attenuated Junin virus vaccine. Proceedings of the 78th
Annual Meeting of the American Society for Virology,
Austin, Texas, June 1988
45.
Cosgriff TM,
Hsiang CM, Huggins JW, Guang MY, Smith JI, Wu ZO, LeDuc
JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PH, Gui XE, Yuan
GH, and Zhang TM. Predictors of fatal outcome in the
severe form of hemorrhagic fever with renal syndrom
(HFRS). Proceedings of the 1st International
Symposium on Hantaviruses and Crimean-Congo Hemorrhagic
Fever Virus, Porto Carras, Halkidiki, Greece, September
1988
46.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and
Oland DD. Treatment of HFRS with high-dose intravenous
ribavirin. Proceedings of the 1st
International Symposium on Hantaviruses and Crimean –
Congo Hemorrhagic Fever virus, Porto Carras, Halkidiki,
Greece, September 1988
47.
Cosgriff TM,
Hsiang CM, Huggins JW, Guang MY, Smith JI, Wu ZO, LeDuc
JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PH, Gui XE, Yuan
GH, and Zhang TM. Predictors of fatal outcome in
epidemic hemorrhagic fever. Proceedings of the
International Symposium on Hemarrhagic Fever with Renal
Syndrome, Wuhan, People’s Republic of China, November
1988
48.
Yuan GH, Huggins JW, Xiang CM,
Cosgriff TM, Guang MY, Smith JI, Cheng LJ, Zhang JR,
Hu JJ, Zhang TH, Zhou WH, Niu CS, Liu XM, Wang DF, Xu
XF, Song JL, and Leng SX. The effects of ribavirin on
serum creatinine clearance rate (Ccr) in patients with
EHF. Proceedings of the International Symposium on
Hemorrhagic Fever with Renal Syndrome, Wuhan, People’s
Republic of China, November 1988
49.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and
Oland DD. Ribavirin therapy of HFRS: overall study of
the efficacy of high-dose intravenous therapy.
Proceedings of the International Symposium on
Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s
Republic of China, November 1988
50.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Zhang MY, Smith JI, Zheng ZM, LeDuc JW,
Hsiang CM, and Meegan JM. Analysis of antigenic
differences among 40 hemarrhagic fever with renal
syndrome (HFRS) virus strains isolated from Hubei by
monoclonal antibody. Proceedings of the International
Symposium on Hemarrhagic Fever with Renal Syndrome,
Wuhan, People’s Republic of China, November 1988
51.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM. Role
of the complement system in the pathogenesis of epidemic
hemorrhagic fever. Proceedings of the International
Symposium on Hemarrhagic Fever with Renal Syndrome,
Wuhan, People’s Republic of China, November 1988
52.
Xiang LB, Chen JM, Zhang ZY, and
Cosgriff TM. Study on mechanisms of hemorrhage,
coagulation and fibrinolysis in EHF patients.
Proceedings of the International Symposium on
Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s
Republic of China, November 1988
53.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, and Smith JI. The effect of C3 and C4
on the pathogenesis of haemorrhage and renal damage in
patients with epidemic haemorrhage fever. Proceedings of
the First Asia-Pacific Congress of Medical Virology,
Singapore, November 1988
54.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Zhang MY, Smith JI, Zhang ZM, LeDuc JW,
Hsiang CM, and Meegan Jm. Analysis of antigenic
differences amoung 40 haemorrhagic fever with renal
syndrome virus isolates from Hubei using monoclonal
antibodies. Proceedings of the First Asia-Pacific
Congress of Medical Virology, Singapore, November 1988
55.
Lewis RM, Ussery MA, and Cosgriff
TM. Immune serum does not enhance infection of
endothelial cells with dengue virus. Blood 1988; 72
(Suppl 1): 1113A
56.
Popovic NA, Oland DD, and Cosgriff
TM. Evaluation of a live, attenuated Venezuelan
equine encephalomyelitis vaccine (TC-83). Proceedings of
the Annual Meeting of the American Society of Tropical
Medicine and Hygiene, Washington, DC, December 1988
57.
Egan JE, Cosgriff TM,
Wasserman GF, Young JF, Wirtz RA, Schneider I,
Hollingdale MR, Chulay JD, and Ballou WR. Immunization
of human volunteers with recombinant Plasmodium
falciparum sporozoite vaccine, R32NSI81. Proceedings of
the Annual Meeting of the American Society of Tropical
Medicine and Hygiene, Washington, DC, December 1988
58.
Rickman LS, Long G, Oberst RB, Egan
JE, Cosgriff TM, Chulay JD, and Hoffman SL. Rapid
diagnosis of malaria by acridine orange staining of
centrifuged parasites. Proceedings of the Annual Meeting
of the American Society of Tropical Medicine and
Hygiene, Washington, DC, December 1988
59.
Cosgriff TM.
The pathophysiology of hemorrhagic fever with renal
syndrome. Proceedings of the 1st
International Conference on Hemarrhagic Fever with Renal
Syndrome, Seoul, Korea, May, 1989
60.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZA, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gibbs PG, Gui XE, Yuan GH, Zhang TM, Oland
DD, and Lee HW. Chemotherapy of HFRS. Proceedings of the
1st International Conference on Hemarrhagic
Fever with Renal Syndrome, Seoul, Korea, May, 1989
61.
Lewis RM, Lee HW, See AF, Parrish DB,
Moon JS, Kim DJ, and Cosgriff TM. Changes in
lymphocyte subpopulations during HFRS. Proceedings of
the 1st International Conference on
Hemarrhagic Fever with Renal Syndrome, Seoul, Korea,
May, 1989
62.
Lewis RM, Lee HW, See AF, Parrish DB,
Moon JS, Kim DJ, and Cosgriff TM. Platelet
aggregation and release in HFRS patients. Proceedings of
the 1st International Conference on
Hemarrhagic Fever with Renal Syndrome, Seoul, Korea,
May, 1989
63.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, and Smith JI. Dynamic observation of
blood system changes in epidemic hemorrhagic fever.
Proceedings of the 1st International
Conference on Hemarrhagic Fever with Renal Syndrome,
Seoul, Korea, May, 1989
64.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM and Smith JI. Detection and clinical
significance of creatine phophate kinase isoenzymes in
epidemic hemorrhagic fever. Proceedings of the 1st
International Conference on Hemarrhagic Fever with Renal
Syndrome, Seoul, Korea, May, 1989
65.
Zhang TM, Huggins JW, Cosgriff TM,
Zhang MY, Smith JI, Zheng ZM, LeDuc JW, Hsiang CM, and
Meegan JM. Antigenic analysis of 40 HFRS virus strains
from Hubei, China. Virus Information Exchange Newsletter
1989; 6:13A
66.
Zhang TM, Hsiang CM, Niu CS, Zhou WH,
Zhang TH, Huggins JW, Cosgriff TM, and Smith JI.
Effect of ribavirin on white blood cells and platelets
in patients with epidemic hemorrhagic fever. Virus
Information Exchanges Newsletter 1989; 6:13A
67.
Zhang TM, Hsiang CM, Niu CS, Zhou WH,
Huggins JW, Cosgriff TM, and Smith JI. Changes in
blood composition of patients with epidemic hemorrhagic
fever. Virus Information Exchange Newsletter 1989; 6:13A
68.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM and Smith JI. Detection and significance
of creatine phophate kinase isoenzymes in epidemic
hemorrhagic fever. Virus Information Exchange Newsletter
1989; 6:13A
69.
Cosgriff TM,
Parrish DB, Major MA, Gong ZJ, and Xiang LB.
Disseminated intravascular coagulation in hemorrhagic
fever with renal syndrome. Thromb Haemost 1989; 62:1163A
70.
Lewis RM, Lee HW, See AF, Parrish DB,
Moon JK, Kim DJ, and Cosgriff TM. The nature of
defective platelet function in patients with hemorrhagic
fever with renal syndrome (HFRS). Thromb Haemost 1989;
62:359A
71.
Cosgriff TM.
Hemorrhagic fever with renal syndrome. Internal Medicine
Digest 1989; 7:13-14A
72.
Cosgriff TM.
Hemorrhagic fever with renal syndrome. Infect Dis Digest
1989; 7:16-18A
73.
Huggins JW, Hsiang CM, Cosgriff TM,
Guang MY, Smith JI, Wu ZA, LeDuc JW, Zheng ZM, Meegan
JM, Wang QN, Gibbs PH, Gui XE, Yuan GH, Zhang TM, Oland
DD, and Lee HW. Ribavirin chemotherapy of hemorrhagic
fever with renal syndrome (HFRS). Proceedings of the
International Symposium on Arboviruses and Arboviral
Infections, Moscow, USSR, October 1989
74.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Guang MY, Smith JI, Zheng ZM, LeDuc JW,
Hsiang CM, and Meegan JM. The isolation and analysis of
HFRS virus from plasma and urine of patients with
epidemic hemorrhagic fever. Proceedings of the
International Symposium on Arboviruses and Arboviral
Infections, Moscow, USSR, October 1989
75.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, and Smith JI. Measurement and clinical
significance of creatine phosphokinase isoenzymes in
epidemic hemorrhagic fever in Wuhan, Hubei Province,
Peoples Republic of China. Proceedings of the
International Symposium of Arboviruses and Arboviral
Infections. Moscow, USSR, October, 1989
76.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, and Smith JI. Observations of
hematologic changes in epidemic hemorrhagic fever in
Wuhan, Hubei Province, Peoples Republic of China.
Proceedings of the International Symposium of
Arboviruses and Arboviral Infecions. Moscow, USSR,
October 1989
77.
Cosgriff TM.
The pathophysiology of hemorrhagic fever with renal
syndrome (HFRS). Proceedings of the International
Society of Nephology Satellite Symposium on
Virus-Related Renal Disease, Kyung, Korea, July 1990
78.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, and Smith JI. Dynamic observations of
blood system changes in epidemic hemorrhagic fever.
Biological Abstracts 1990; 89:27137A
79.
Wang FS, Cosgriff TM, and
Bunner DL. Effects of cytokines on the protein C and
protein S concentration in supernates from Hep G2 cell
culture. Blood 1990; 76 (Suppl 1):442A
80.
Cosgriff TM.
Mechanisms of disease in Hantavirus infection:
Pathophysiology of hemorrhagic fever with renal
syndrome. Infect Dis Digest 1991
81.
Zhang TM, Huggins JW, Yang ZQ,
Cosgriff TM, Zhang MY, Smith JI, and Zhang TH.
Relationships between kidney damage, viremia, complement
levels, and prognosis in epidemic hemorrhagic fever
patients. Virus Information Exchange Letter 1991; 8:121A
82.
Zhang TM, Huggins JW, Hsiang CM,
Cosgriff TM, Zhou WH, Smith JI, and Hu ZJ. Analysis
of viremia and clinical findings in patients with
epidemic hemorrhagic fever in the early phase.
Proceedings of the Second International Conference on
Hemorrhagic Fever with Renal Syndrome, Beijing, People’s
Republic of China, October, 1992
83.
Yuan GH, Wang SJ, Lin H, Guang MY,
Zhang XI, Huggins JW, Cosgriff TM, and Smith JI.
Investigation of the relationship between creatinine
clearance rate and other renal function indices in HFRS.
Proceedings of the second Intenational Conference on
Hemorrhagic Fever with Renal Syndrom, Beijing, People’s
Republic of China, October, 1992
84.
Smith JI, Xing SF, Cosgriff TM,
Yi XP, and Huggins JW. Retrospective and prospective
controlled study of the gross and microscopic pathology
of 18 patients who died of epidemic hemorrhagic fever in
Hubei Province, People’s Republic of China. Proceedings
of the Annual Meeting of the American Society of
Clinical Pathology/College of American Pathologists,
Anaheim California, October, 1993
85.
Smith JI, Xing SF, Cosgriff TM,
Yi XP, Tong ZG, and Huggins JW. Retrospective and
prospective controlled study of the immunopathology of
18 patients who died of epidemic hemorrhagic fever in
Hubei Province, People’s Republic of China. Proceedings
of the Annual Meeting of the Society of Armed Forces
Medical Laboratory Scientists, March, 1994
86.
Cosgriff TM,
Black ML, and Stein W, III. Liposomal doxorubicin
produces remissions in severe refractory idiopathic
thrombocytopenic purpura. Blood 1997; 90:3078A
87.
Veloso
D, Smith JI, and Cosgriff TM. Rhesus
differential susceptibility to endotoxin is not
associated with prekallikrein activation. The 15th
International Conference on Kinins, Nara, Japan,
September, 1998
88.
Cosgriff TM,
Black ML, and Stein W, III. Severe refractory
idiopathic thrombocytopenic purpura responds to
liposomal doxorubicin. Thromb Haemost 1999; 82:1941A
89.
Veloso
D, Smith JI, Guynn RW, and Cosgriff TM.
Differentiated and undifferentiated responses or rhesus
monkeys to high doses of endotoxin. Thromb Haemost
1999;82:33A
90.
Perez EA, Lambert-Falls R, Deutsch M,
Desch C, Justice G, Cosgriff T, Headly D, and
Palmieri FM. Phase II adjuvant trial of concurrent
epirubicin/taxan versus sequential
epirubicin/cyclosphosphamide followed by taxane for
node-positive breast cancer; safety analysis. 25th
Annual San Antonio Breast Cancer Symposium, San Antonio,
Texas, December, 2002
91.
Bhatnagar A, Carmicahel J,
Cosgriff T, Harper P, Steward W, Birdgewater J,
Moore M, Redfern C, Valone F and Cunningham D. A
Randomized, double-blind, placebo controlled phase III
study of monoclonal antibody 3H1 plus 5-fluorouracil
(5-FU)/Leucovorin (LV) in state IV colorectal carcinoma.
J Clin Oncol 2003; 22:1041A
92.
Reid T, Weeks AE, Vakil M,
Cosgriff T, Harper H, Yen K, Scislowski P,
Scappaticci F, Valone F, and Bhatnagar A. Dose
escalation study of pivanex (a histone deacetylase
inhibitor) in combination with docetaxel for advanced
non-small cell lung cancer. 10th World
Conference on Lung Cancer, Vancouver, British Columbia,
August 12, 2003.
93.
Reid T, Weeks AE,
Cosgriff T, Harper T, Valone F, Magnuson D, and
Bhatnagar A. Dose escalation study of Pivanex (A Histone
Deacetylase Inhibitor) in combination with Docetaxel for
Advanced Non-Small Cell Lung Cancer. ASCO 40th
Annual Meeting, Ernest N. Morial Convention Center, New
Orleans, LA, June 5-8, 2004.
94.
Boccia RV, Dakhil S,
Cosgriff T, Pink C, Butler B. Cetuximab + FOLFOX 6
as first line therapy for metastatic colorectal cancer.
Preliminary safety results. J Clin Oncol 2004; 22:
95.
Scott J, Dakhil S,
Cosgriff T, Pink C, Butler B, Boccia RV, Cetuximab +
FOLFOX 6 as first line therapy for metastatic colorectal
cancer. J Clin Oncol 2005; 23:3705A
96.
Lyons R, Cosgriff T,
Modi S, Lintz L, Beach CL, PharmD, and Backstrom J.
Azacitidine (Vidaza) treatment response assessed using
three alternative dosing schedules in patients with
myelodysplastic syndromes (MDS). Blood 2005: 106:2517A
97.
Dakhil S, Cosgriff T,
Headley D, Boccia RV, Badarinath S, Cetuximab + FOLFOX 6
as first line therapy for metastatic colorectal cancer.
J Clin Oncol 2006; 25:3557A
98.
Anthony S, Lyons R,
Cosgriff T, Modi S. Transfusion independence
assessed using three alternative dosing schedules of
azacytidine in patient with myelodysplastic syndrome
(MDS). J Clin Oncol 2006; 24:6574A
99.
Mirtsching B, Chidiac T, Cosgriff T.
First-line treatment of
metastic breast cancer with weekly Abraxane
(nab-paclitaxel: a 130nm albumin-bound paclitaxel
particle: a preliminary analysis of the phase II
International Oncology Network ION-04-012 study. J Clin
Oncol 2006; 24:10707A
100.
Mirtsching BC, Cosgriff T, Chidiac
T, Harker G, Keaton M, Min M.
First-line treatment of metastatic breast
cancer with weekly Abraxane (an International Oncology
Network Study, ION-04-012.) Accepted for presentation at
the 29th Annual San Antonio Breast Cancer
Symposium, San Antonio, Texas, December, 2006.
BOOK
REVIEWS
1.
Seifter EJ,
Bell WR. Coagulation Disorders in the Cancer Patient.
Mount Kisco, New York Futura Publishing Co., Mount Kisco,
New York: Futura Publishing Co.; 1984. In Critical Care
Medicine
1985; 13:697